What would you do if you suddenly woke up blind?
Would you know how to install a screen reader to read an article like this?
Although it’s a hypothetical question, this is a reality for some who suffer from glaucoma.
Glaucoma is an eye disease caused by excess eye pressure.
It’s painful and sometimes leads to complete blindless.
Meaning, one day you could be crushing life and the next day you don’t have a driver’s license anymore.
Men who lose their eyesight say it’s the loneliest and most isolating experience they’ve ever known.
However, with the right lifestyle adjustments, glaucoma is a preventable disease.
One effective strategy is reducing your caffeine intake.
A New York medical study found frequent caffeine intake could increase the risk of glaucoma by 200% for those genetically at risk for high eye pressure.[R]
Meaning, it’s best to cut back on coffee if glaucoma or high eye pressure runs in your family.
One of the researchers, Dr. Anthony Khawaka, makes it clear that this link is only noticeable in those who are already at risk.
Here’s how he puts it:
“This study suggested that those with the highest genetic risk for glaucoma may benefit from moderating their caffeine intake. It should be noted that the link between caffeine and glaucoma risk was only seen with a large amount of caffeine and in those with the highest genetic risk.”
According to these findings, if glaucoma runs in your family, reducing your caffeine intake should be your number one priority.
Thankfully, caffeine in moderation is fine.
One or two cups of coffee should be enough to give you the daily kick you need anyway.
After hitting that limit, decaf is the way to go.
Your eyes will thank you.
Ouro Vitae, A First Finisher LLC Company, 900 Commonwealth Place PMB 2135 Virginia Beach, VA 23464
*These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.
©2022 Ouro Vitae. All rights reserved.
1. Cavallini, G., Caracciolo, S., Vitali, G., Modenini, F., & Biagiotti, G. (2004). Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology, 63(4), 641-646. doi:10.1016/j.urology.2003.11.009
2. Malaguarnera, M., Cammalleri, L., Gargante, M. P., Vacante, M., Colonna, V., & Motta, M. (2007). L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: A randomized and controlled clinical trial. The American Journal of Clinical Nutrition, 86(6), 1738-1744. doi:10.1093/ajcn/86.5.1738
3. Karlic, H., & Lohninger, A. (2004). Supplementation of l-carnitine in athletes: Does it make sense? Nutrition, 20(7-8), 709-715. doi:10.1016/j.nut.2004.04.003
4. Samimi, M., Jamilian, M., Ebrahimi, F. A., Rahimi, M., Tajbakhsh, B., & Asemi, Z. (2016). Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Clinical Endocrinology,84(6), 851-857. doi:10.1111/cen.13003
5. Sahlin, K. (2011). Boosting fat burning with carnitine: An old friend comes out from the shadow. The Journal of Physiology, 589(7), 1509-1510. doi:10.1113/jphysiol.2011.205815
6. Soczynska, J. K., Kennedy, S. H., Chow, C. S., Woldeyohannes, H. O., Konarski, J. Z., & Mcintyre, R. S. (2008). Acetyl-L-carnitine and α-lipoic acid: Possible neurotherapeutic agents for mood disorders? Expert Opinion on Investigational Drugs, 17(6), 827-843. doi:10.1517/13543784.17.6.827
7. Miyagawa, T., Kawamura, H., Obuchi, M., Ikesaki, A., Ozaki, A., Tokunaga, K., . . . Honda, M. (2013). Effects of Oral L-Carnitine Administration in Narcolepsy Patients: A Randomized, Double-Blind, Cross-Over and Placebo-Controlled Trial. PLoS ONE,8(1). doi:10.1371/journal.pone.0053707
8. Cristofano, A., Sapere, N., Marca, G. L., Angiolillo, A., Vitale, M., Corbi, G., . . . Costanzo, A. D. (2016). Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimers Dementia. Plos One, 11(5). doi:10.1371/journal.pone.0155694
. Fillit, H., & Hill, J. (2004). The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias. Alzheimer Disease & Associated Disorders,18. doi:10.1097/01.wad.0000127492.65032.d3
10. Miyata, M., Yoshihisa, A., Yamauchi, H., Owada, T., Sato, T., Suzuki, S., . . . Takeishi, Y. (2014). Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure. Heart and Vessels, 30(3), 318-324. doi:10.1007/s00380-014-0479-6
11. Lango, R. (2001). Influence of ?-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovascular Research, 51(1), 21-29. doi:10.1016/s0008-6363(01)00313-3
12. Vescovo, G., Ravara, B., Gobbo, V., Sandri, M., Angelini, A., Barbera, M. D., . . . Libera, L. D. (2002). L-Carnitine: A potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. American Journal of Physiology-Cell Physiology, 283(3). doi:10.1152/ajpcell.00046.2002
13. Shadboorestan, A., Shokrzadeh, M., Ahangar, N., Abdollahi, M., Omidi, M., & Payam, S. S. (2013). The chemoprotective effects of l-carnitine against genotoxicity induced by diazinon in rat blood lymphocyte. Toxicology and Industrial Health,31(12), 1334-1340. doi:10.1177/0748233713491811
14. Chowanadisai, W., Bauerly, K. A., Tchaparian, E., Wong, A., Cortopassi, G. A., & Rucker, R. B. (2009). Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression. Journal of Biological Chemistry,285(1), 142-152. doi:10.1074/jbc.m109.030130
15. Chowanadisai, W., Bauerly, K. A., Tchaparian, E., Wong, A., Cortopassi, G. A., & Rucker, R. B. (2009). Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression. Journal of Biological Chemistry, 285(1), 142-152. doi:10.1074/jbc.m109.030130
16. Stites TE, Mitchell AE, Rucker RB. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr. 2000 Apr;130(4):719-27
17. Steinberg, F., Stites, T. E., Anderson, P., Storms, D., Chan, I., Eghbali, S., & Rucker, R. (2003). Pyrroloquinoline Quinone Improves Growth and Reproductive Performance in Mice Fed Chemically Defined Diets. Experimental Biology and Medicine, 228(2), 160-166. doi:10.1177/153537020322800205
18. Biswas, T. K., Pandit, S., Mondal, S., Biswas, S. K., Jana, U., Ghosh, T., . . . Auddy, B. (2010). Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. Andrologia,42(1), 48-56. doi:10.1111/j.1439-0272.2009.00956.x
19. Surapaneni, D. K., Adapa, S. R., Preeti, K., Teja, G. R., Veeraragavan, M., & Krishnamurthy, S. (2012). Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic–pituitary–adrenal axis and mitochondrial bioenergetics in rats. Journal of Ethnopharmacology, 143(1), 91-99. doi:10.1016/j.jep.2012.06.002
20. Chang, C. S., Choi, J. B., Kim, H. J., & Park, S. B. (2011). Correlation Between Serum Testosterone Level and Concentrations of Copper and Zinc in Hair Tissue. Biological Trace Element Research,144(1-3), 264-271. doi:10.1007/s12011-011-9085-y
21. Plasma Steroid-Binding Proteins in Tumour Diseases. (1984). Molecular Aspects of Medicine, 371-380. doi:10.1016/b978-0-08-033239-0.50032-6
